Peptides Vietnam LogoPeptides Vietnam
MetabolicEvidence ReviewUpdated Sep 2026

Microdosing GLP-1s: Does It Work? Benefits and Risks

Microdosing GLP-1 medicines means using doses smaller than the approved labelled amounts of a GLP-1 receptor agonist such as semaglutide or tirzepatide. It is an off-label practice that spread through the compounding market, direct-to-consumer telehealth, and social media, not a regimen any clinical trial has tested. This page defines the term, shows what the FDA labels actually prescribe, and reports what dose-response trials found at their lowest doses. The honest bottom line comes first: no trial has tested microdosing as a regimen, so there is no evidence-based microdose, schedule, or expected result to give. Everything here is education, not medical advice, and nothing on this page tells anyone what to take.

This is general education, not medical advice, and not a dosing guide. Every milligram figure below is either an FDA label dosage or a clinical trial arm, reported exactly as its source states it, and none of it is a recommendation. No clinical trial has tested a microdosing regimen for any GLP-1 medicine, so this page cannot and does not give a microdose, a schedule, or a promised result. GLP-1 medicines are prescription drugs, and any decision about them belongs with a licensed clinician, not a webpage.

Off-label

A practice, not a defined clinical protocol

0 trials

Have tested microdosing as a regimen

Prescription

GLP-1 medicines require a clinician

What Microdosing GLP-1 Means

Microdosing a GLP-1 medicine means using smaller, fractional doses of a GLP-1 receptor agonist than the approved amounts. News-Medical describes it as "smaller, fractional doses of a medication that may allow patients to receive some therapeutic benefits while extending their use of the medication."1 A 2026 commentary in Expert Opinion on Pharmacotherapy frames microdosing of single or dual GLP-1 receptor agonists as an off-label strategy to improve tolerability, reduce cost, and expand access during periods of medication shortages.2The key word is off-label. Microdosing is a practice, not a defined clinical protocol, and it is not written into any drug's label.

That distinction matters, because every GLP-1 label in this guide already starts low and climbs. The same Expert Opinion on Pharmacotherapy commentary reports that microdosing is typically defined as 25 to 50% of manufacturer-recommended starting doses (community practice, no trial), or extended dosing intervals (community practice, no trial).2 The same commentary says the practice gained traction during recent shortages through patient communities, telemedicine-based weight loss programs, and clinician anecdotes,2 and no label or trial sets a microdose figure or schedule. That is different from the deliberately slow titration the labels build in as they climb toward maintenance. The labelled initiation and titration steps are ordinary labelled dosing, not microdoses, so the labelled starting doses and the trial doses further down this page are the reference points microdosing departs from, not examples of it.

The shortage and compounding record this page documents concerns tirzepatide and semaglutide. The detail pages for each are the microdosing tirzepatide and microdosing semaglutide guides, which work through each label and the community practices around it. This page does not cover the general GLP-1 side-effect profile or the head-to-head comparison; those live in the GLP-1 side effects and tirzepatide vs semaglutide guides.

Where the Practice Comes From

Microdosing did not come out of a laboratory. It spread through the GLP-1 compounding market, direct-to-consumer telehealth companies, drug shortages, cost pressure, and social media. STAT reported that microdosing "aims to extend the lifespan of the GLP-1 compounding market," and that marketing claims about GLP-1s in small doses are not backed by robust clinical evidence.4 A brief report in the Journal of the American Association of Nurse Practitioners situates the microdosing dilemma in the period after the FDA resolved the semaglutide and tirzepatide shortages, when the legal basis for compounding narrowed.5 The Expert Opinion commentary ties the practice to the same forces: tolerability, cost, access, and shortages.2

Compounding grew during a genuine nationwide shortage. The FDA added tirzepatide injection products to its drug shortage list on December 15, 2022,26 and semaglutide injection products earlier the same year, Wegovy in March 2022 and Ozempic in August 2022, according to the FDA semaglutide Declaratory Order, which also describes the shortage-list conditions under which federal law lets pharmacies and outsourcing facilities compound copies of an approved drug.27 The FDA attributes the semaglutide shortages to increased demand.25

Then the shortages ended. The FDA determined the tirzepatide shortage resolved on December 19, 2024,26 and the semaglutide shortage resolved on February 21, 2025.27 Each resolution came with short enforcement-discretion wind-downs, after which the shortage-based reason to compound copies ends: for semaglutide, state-licensed pharmacies had until April 22, 2025 and outsourcing facilities until May 22, 2025.27 The FDA says the enforcement-discretion period for semaglutide has ended, while noting that patients may still see intermittent local supply disruptions even after a shortage is officially resolved.2527 Microdosing, stretching a vial further with smaller amounts, is one response to that squeeze. STAT quotes Reshma Ramachandran, a health services researcher and clinician at Yale School of Medicine, warning that "essentially these patients are guinea pigs, both on the efficacy side and the safety side."4

The Labelled Titration Schedules

Microdosing is defined against the labelled dose, so here is what the labels actually set. Every figure in this section is an FDA label dosage. The WEGOVY, OZEMPIC, and MOUNJARO labels each tie their escalation schedule to reducing the risk of gastrointestinal adverse reactions, and every label here starts at a low initiation dose that it then titrates upward.

Read the table as reference, not instruction. Every figure below is an FDA label dosage, reported as the label states it. None of it is a recommendation, a microdose, or a starting point for anyone to copy.

Medicine (labelled)Starting doseTitrationMaintenance and maximumSource
Wegovy injection (semaglutide)0.25 mg once weekly (labelled dose, not a recommendation, WEGOVY FDA label)Every 4 weeks: 0.25, then 0.5, 1, 1.7 mg (labelled dose, not a recommendation, WEGOVY FDA label)The WEGOVY label lists maintenance of 1.7 or 2.4 mg and names 2.4 mg as its recommended option; a 7.2 mg maximum for weight reduction, only after tolerating 2.4 mg for at least 4 weeks and when additional weight reduction is clinically indicated (labelled dose, not a recommendation, WEGOVY FDA label)DailyMed / novo-pi
Wegovy tablets (oral semaglutide)1.5 mg once daily (labelled dose, not a recommendation, WEGOVY FDA label)Days 1 to 30: 1.5 mg; 31 to 60: 4 mg; 61 to 90: 9 mg (labelled dose, not a recommendation, WEGOVY FDA label)Maintenance 25 mg once daily (labelled dose, not a recommendation, WEGOVY FDA label)novo-pi / DailyMed
Ozempic (semaglutide)0.25 mg once weekly for 4 weeks (labelled dose, not a recommendation, OZEMPIC FDA label)The OZEMPIC label increases to 0.5, then, if additional glycemic control is needed, 1 then 2 mg (at least 4 weeks per step) (labelled dose, not a recommendation, OZEMPIC FDA label)Maintenance 0.5, 1 or 2 mg; maximum 2 mg (labelled dose, not a recommendation, OZEMPIC FDA label)FDA PI / DailyMed
Zepbound (tirzepatide)The ZEPBOUND label sets 2.5 mg once weekly for 4 weeks, for initiation only (labelled dose, not a recommendation, ZEPBOUND FDA label)To 5 mg, then 2.5 mg increments after at least 4 weeks (labelled dose, not a recommendation, ZEPBOUND FDA label)Maintenance 5, 10 or 15 mg (OSA 10 or 15); maximum 15 mg (labelled dose, not a recommendation, ZEPBOUND FDA label)pi.lilly / DailyMed
Mounjaro (tirzepatide)2.5 mg once weekly (labelled dose, not a recommendation, MOUNJARO FDA label)2.5 mg increments after at least 4 weeks on a dose, if additional glycemic control is needed (labelled dose, not a recommendation, MOUNJARO FDA label)Maximum 15 mg (adults); 10 mg (pediatric 10 years and older) (labelled dose, not a recommendation, MOUNJARO FDA label)pi.lilly / DailyMed

For semaglutide, the WEGOVY injection label sets a starting dosage of 0.25 mg subcutaneously once weekly (labelled dose, not a recommendation, WEGOVY FDA label). Its escalation steps, spaced every four weeks, are 0.5 mg (labelled dose, not a recommendation, WEGOVY FDA label), 1 mg (labelled dose, not a recommendation, WEGOVY FDA label), and 1.7 mg (labelled dose, not a recommendation, WEGOVY FDA label). The label sets maintenance at 2.4 mg once weekly (labelled dose, not a recommendation, WEGOVY FDA label), with an alternative of 1.7 mg (labelled dose, not a recommendation, WEGOVY FDA label). For weight reduction in adults, it lists a high-dose pen maximum of 7.2 mg (labelled dose, not a recommendation, WEGOVY FDA label), only after tolerating 2.4 mg for at least 4 weeks (labelled dose, not a recommendation, WEGOVY FDA label) and when additional weight reduction is clinically indicated.1213 The current label also carries oral WEGOVY tablets, starting at 1.5 mg once daily (labelled dose, not a recommendation, WEGOVY FDA label), then rising through 4 mg (labelled dose, not a recommendation, WEGOVY FDA label) and 9 mg (labelled dose, not a recommendation, WEGOVY FDA label) to maintenance of 25 mg once daily (labelled dose, not a recommendation, WEGOVY FDA label).1312 The OZEMPIC label, for the semaglutide injection for type 2 diabetes, sets initiation at 0.25 mg once weekly for four weeks (labelled dose, not a recommendation, OZEMPIC FDA label), then an increase to 0.5 mg (labelled dose, not a recommendation, OZEMPIC FDA label). It lists maintenance options of 0.5 mg (labelled dose, not a recommendation, OZEMPIC FDA label), 1 mg (labelled dose, not a recommendation, OZEMPIC FDA label), or 2 mg (labelled dose, not a recommendation, OZEMPIC FDA label), and a maximum of 2 mg (labelled dose, not a recommendation, OZEMPIC FDA label).1415

For tirzepatide, the ZEPBOUND label sets initiation at 2.5 mg once weekly for four weeks (labelled dose, not a recommendation, ZEPBOUND FDA label), then an increase to 5 mg (labelled dose, not a recommendation, ZEPBOUND FDA label). Further increases are in steps of 2.5 mg after at least four weeks on a dose (labelled dose, not a recommendation, ZEPBOUND FDA label). The label lists maintenance options of 5 mg (labelled dose, not a recommendation, ZEPBOUND FDA label), 10 mg (labelled dose, not a recommendation, ZEPBOUND FDA label), or 15 mg (labelled dose, not a recommendation, ZEPBOUND FDA label), and a maximum of 15 mg (labelled dose, not a recommendation, ZEPBOUND FDA label).1617 MOUNJARO, the tirzepatide label for type 2 diabetes, sets the same start of 2.5 mg once weekly (labelled dose, not a recommendation, MOUNJARO FDA label), with increases in increments of 2.5 mg (labelled dose, not a recommendation, MOUNJARO FDA label). It sets a maximum for adults of 15 mg (labelled dose, not a recommendation, MOUNJARO FDA label), and for eligible pediatric patients of 10 mg (labelled dose, not a recommendation, MOUNJARO FDA label).1819

Here is the point that matters for microdosing. The lowest step the injection labels prescribe is a once-weekly initiation dose; the oral WEGOVY tablet starts at 1.5 mg once daily (labelled dose, not a recommendation, WEGOVY FDA label), each a starting point the label then titrates upward from, as the brand-specific figures in the table and the two paragraphs above set out. The ZEPBOUND label is the most explicit: it states outright that its dose of 2.5 mg (labelled dose, not a recommendation, ZEPBOUND FDA label) is for treatment initiation and is not approved as a maintenance dosage.1617 The MOUNJARO label instead escalates in increments of 2.5 mg (labelled dose, not a recommendation, MOUNJARO FDA label) if additional glycemic control is needed and names a maximum rather than a discrete maintenance dose.1819 Microdosing departs from those labelled amounts with smaller, fractional doses, which is precisely the move no label describes. For retatrutide, the when will retatrutide be available guide covers where that stands.

What Dose-Response Trials Show at Low Doses

There is no trial of microdosing, but there are trials that tested these drugs across a range of doses, including low ones. These are the closest thing to relevant data, and News-Medical is careful to call them exactly that: the studies provide "indirect support rather than direct evidence from trials specifically designed to test a microdosing strategy."1 Here is what the low arms showed.

A phase 2 dose-ranging obesity trial published in The Lancet in 2018 tested once-daily semaglutide across a low range, from 0.05 mg per day (trial dose, not a recommendation, PMID 30122305) to 0.4 mg per day (trial dose, not a recommendation, PMID 30122305). Every semaglutide arm started at 0.05 mg per day and escalated every four weeks (trial dose, not a recommendation, PMID 30122305).20 The trial reported estimated mean weight loss that generally rose with dose: about 6.0% at 0.05 mg (trial dose, not a recommendation, PMID 30122305), 8.6% at 0.1 mg (trial dose, not a recommendation, PMID 30122305), 11.6% at 0.2 mg (trial dose, not a recommendation, PMID 30122305), 11.2% at 0.3 mg (trial dose, not a recommendation, PMID 30122305), and 13.8% at 0.4 mg (trial dose, not a recommendation, PMID 30122305), against about 2.3% on placebo.20 These are once-daily doses, not the once-weekly schedule the approved semaglutide injections use, so the two cannot be lined up milligram for milligram. In that randomized phase 2 trial (PMID 30122305), the low-dose groups lost more weight than the placebo group. It is also a supervised dose-ranging experiment, not a microdosing regimen anyone followed for months or years.

The pivotal tirzepatide trials point the same way, and the one fact that matters here is the dose they started from. The lowest tirzepatide arm in the phase 3 obesity trial SURMOUNT-1 was 5 mg once weekly (trial dose, not a recommendation, PMID 35658024),21 and the lowest tirzepatide arm in the type 2 diabetes trial SURPASS-2 was also 5 mg once weekly (trial dose, not a recommendation, PMID 34170647).22 That 5 mg is already the tirzepatide label's first maintenance dose, one titration step above its 2.5 mg initiation dose (labelled dose, not a recommendation, ZEPBOUND FDA label),16 so neither pivotal trial went anywhere near a microdose. The full head-to-head weight and glucose results from these two trials live in the tirzepatide vs semaglutide guide, which this page does not restate.

One phase 2 dose-ranging trial of once-daily semaglutide found weight loss at its lowest arm,20 and the lowest doses the big trials actually tested were not microdoses.2122 The once-daily semaglutide study cannot be lined up milligram for milligram with the once-weekly injection labels, and the lowest tirzepatide arm the pivotal trials tested was already that drug's first labelled maintenance dose. The gap between "low doses do something" and "this specific microdose, on this schedule, is safe and works" is the gap no trial has closed.

No Trial Has Tested Microdosing as a Regimen

This is the heart of it. No clinical trial has tested microdosing GLP-1 as a regimen. A PubMed search on September 29, 2026 for microdosing combined with GLP-1, semaglutide, or tirzepatide returned only eleven records, and reading every one shows that none is a clinical trial of a microdosing regimen.11 What exists is commentary, a narrative review, letters, and a brief report: a 2026 commentary on the considerations and challenges of microdosing GLP-1 based agonists,2 a narrative review of claimed multisystem benefits,6 two pieces in Obesity on microdosing tirzepatide in multi-dose pens,78 a nurse-practitioner brief report on the microdosing dilemma,5 and a Diabetes Care letter with its comment on microdosing semaglutide in multidose pens.910 The remaining four hits are not clinical trials of a GLP-1 microdosing regimen: a lithium paper on Parkinson's disease,35 an LC-MS/MS assay paper on the feasibility of supporting a clinical microdose study of danuglipron,36 an anti-obesity microneedle gene-therapy paper,37 and a psilocybin mouse study.38 Not one is a randomized clinical trial of a GLP-1 microdosing regimen.

The people who study this say so directly. News-Medical notes that studies on microdosing GLP-1 receptor agonists are "extremely limited" and offer "indirect support rather than direct evidence from trials specifically designed to test a microdosing strategy."1 In a STAT First Opinion, the weight-loss physician Jody Dushay put it bluntly: "Microdosing GLP-1s is not a thing. There are no legitimate long-term data to support it," adding that compounded microdose products have not been studied, short or long term, for safety, efficacy, or weight regain after stopping.3 STAT's news reporting adds that the marketing claims are not backed by robust clinical evidence.4

The honest bottom line. Because no trial has tested it, there is no evidence-based microdose, no validated schedule, and no expected result to quote. What circulates instead is a mix of hope, anecdote, and marketing. That is worth knowing plainly before reading anything that presents a microdose as a settled number.

What the FDA Reports on Compounded GLP-1

In a July 2024 alert, the FDA reported that it had received reports of adverse events, some requiring hospitalization, that may be related to overdoses due to dosing errors with compounded injectable semaglutide, where patients or providers measured and administered the dose themselves. The agency described patients drawing from multiple-dose vials who administered five to twenty times more than the intended dose (FDA safety alert figure, not a recommendation). In one pattern, the FDA reported an administered amount of 50 units (FDA safety alert figure, not a recommendation) against a prescribed amount of 5 units (FDA safety alert figure, not a recommendation). It also reported provider miscalculations converting milligrams to units that led patients to receive five to ten times the intended dose (FDA safety alert figure, not a recommendation).23 Reported effects included nausea, vomiting, abdominal pain, fainting, dehydration, acute pancreatitis, and gallstones, and the FDA noted that overdose symptoms may need prolonged observation and treatment because semaglutide has a roughly one-week half-life.23

The current FDA page on unapproved GLP-1 drugs reports that, as of May 31, 2026, it had received 990 adverse-event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide, including reports connected to doses beyond what is in the approved label.24 It warns separately about counterfeit Ozempic marketed in the United States that could contain the wrong ingredient, or too little, too much, or no active ingredient at all.24 The standing FDA position is that compounded drugs do not undergo its premarket review for safety, quality, or effectiveness and should be used only when a patient's needs cannot be met by an approved drug.23

None of this is a verdict on any one product, but it is why the measuring step is not a detail. For related reading on spotting fakes and on how these medicines reach the market here, see the guides on counterfeit Ozempic in Vietnam and GLP-1 medicines in Vietnam.

Other Peptides People Ask About Microdosing

Microdosing gets attached to a lot of injectable peptides beyond the GLP-1 drugs, and most of that talk runs far ahead of the evidence. Here is one honest line on each, with its evidence level and no microdosing protocol to copy for any of them. These are short by design. None gets a microdosing protocol here, because none has one worth reporting.

NAD+No eligible IV or IM outcomes trials

A 2026 PRISMA-guided systematic review found no eligible outcomes trials evaluating intravenous or intramuscular NAD+ itself for anti-aging or wellness indications, so that review provides no outcomes-trial dose of IV or IM NAD+ itself for those indications, microdose or otherwise. 28

TesamorelinFDA-approved drug, labelled dosing

Tesamorelin is FDA-approved as EGRIFTA SV, a growth-hormone-releasing factor analog for reducing excess abdominal fat in HIV-associated lipodystrophy, at a labelled dose of 1.4 mg injected subcutaneously once daily (labelled dose, not a recommendation, EGRIFTA SV FDA label). That is a full daily dose for a specific approved indication, not a microdosing protocol. 29

MOTS-cNo clinical application method developed

MOTS-c is a mitochondrial-derived peptide still at an early research stage. A 2023 review in Frontiers in Endocrinology notes it has been used less frequently in disease treatment and that no effective method of applying it in the clinic has been developed, so there is no established clinical dose to report, microdose or otherwise. 30

PT-141 (bremelanotide)FDA-approved drug, labelled dosing

PT-141, or bremelanotide, is FDA-approved as VYLEESI for premenopausal women with acquired, generalized hypoactive sexual desire disorder, at a labelled dose of 1.75 mg injected subcutaneously (labelled dose, not a recommendation, VYLEESI FDA label). The label specifies no more than one dose within 24 hours (labelled dose, not a recommendation, VYLEESI FDA label) and states that more than eight doses per month is not recommended (labelled dose, not a recommendation, VYLEESI FDA label). It is an as-needed drug for one indication, not a microdosed daily peptide. 31

SermorelinNo marketed FDA-approved product

Sermorelin is a growth-hormone-releasing hormone analog. Its only FDA-approved product, GEREF, was approved in 1997 and discontinued by its maker in 2008, and the FDA determined it was not withdrawn for reasons of safety or effectiveness. No marketed FDA-approved sermorelin exists today, so there is no currently marketed approved product or labelled dose to report. 32

BPC-157Unapproved, FDA-flagged risks

BPC-157 is not FDA-approved. In its review of bulk substances for compounding, the FDA stated that compounded BPC-157 may pose a risk of immunogenicity for certain routes of administration and may have peptide-characterization complexities, and that the agency lacks sufficient information to know whether it would cause harm when administered to humans. It sits as an unapproved compound with flagged risks and no established human dose. 33

Liraglutide (Saxenda)FDA-approved GLP-1, labelled dosing

Liraglutide is an FDA-approved GLP-1 receptor agonist marketed as SAXENDA for chronic weight management, dosed once daily with a real titration: 0.6 mg to start, rising in weekly steps through 1.2, 1.8, and 2.4 mg to a 3 mg maintenance dose (labelled dose, not a recommendation, SAXENDA FDA label). The label calls the lower steps titration only, not a maintenance regimen. 34

The Short Version

  • Microdosing a GLP-1 medicine means using doses smaller than the approved labelled amounts; it is an off-label practice, not a defined clinical protocol.
  • It spread through the GLP-1 compounding market, telehealth, drug shortages, cost pressure, and social media, not through clinical research.
  • The FDA labels build in a slow climb: each injection starts at a low once-weekly initiation dose, and the oral WEGOVY tablet at a once-daily starting dose, which the label then titrates upward. Microdosing departs from those labelled amounts with smaller, fractional doses that no label or trial defines. The brand-specific figures are in the table above.
  • In the phase 2 dose-ranging obesity trial, once-daily semaglutide from 0.05 mg (trial dose, not a recommendation, PMID 30122305) beat placebo. In SURMOUNT-1, tirzepatide from a 5 mg arm (trial dose, not a recommendation, PMID 35658024) also beat placebo, but that lowest tirzepatide arm was already the ZEPBOUND label's first maintenance dose (labelled dose, not a recommendation, ZEPBOUND FDA label).
  • No clinical trial has tested microdosing as a regimen. A September 2026 PubMed search returned eleven records and none is a microdosing trial.
  • Because no trial has tested it, there is no evidence-based microdose, schedule, or expected result to quote.
  • As of May 31, 2026, the FDA had logged 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide. It separately reports events that may be related to dosing errors and to doses beyond the approved label.
  • For other peptides tied to microdosing talk (NAD+, tesamorelin, MOTS-c, PT-141, sermorelin, BPC-157, liraglutide), the evidence runs from approved labels to preclinical only, and none has a microdosing protocol worth reporting.

Frequently asked questions

What is microdosing GLP-1?+

Microdosing a GLP-1 medicine means using doses smaller than the approved labelled amounts of a GLP-1 receptor agonist such as semaglutide or tirzepatide. Sources describe it as an off-label practice aimed at tolerability, cost, and access, not a defined clinical protocol, and no drug label includes a microdose. It is a practice, not a prescription.

Is there a recommended GLP-1 microdose?+

No. No clinical trial has tested a microdosing regimen for any GLP-1 medicine, so there is no evidence-based microdose, no validated schedule, and no expected result to state. Every milligram figure in the published clinical record cited on this page is either an FDA label dosage or a clinical trial arm, and none of those is a microdose. This page reports those figures as education, not as a dose for anyone to copy.

Does microdosing GLP-1 work for weight loss?+

There is no direct evidence either way, because no trial has tested it. In one phase 2 dose-ranging obesity trial, the lowest once-daily semaglutide dose of 0.05 mg (trial dose, not a recommendation, PMID 30122305) beat placebo, but News-Medical describes this as indirect support rather than evidence from a trial designed to test microdosing. The lowest tirzepatide dose in the pivotal trials cited here was 5 mg once weekly (trial dose, not a recommendation, PMID 35658024), which the ZEPBOUND label already sets as a first maintenance dose (labelled dose, not a recommendation, ZEPBOUND FDA label), not a microdose.

Where did GLP-1 microdosing come from?+

It spread through the GLP-1 compounding market, direct-to-consumer telehealth companies, drug shortages, cost pressure, and social media, not through clinical research. Compounding grew during the 2022 to 2025 shortages of semaglutide and tirzepatide; after the FDA declared those shortages resolved in December 2024 and February 2025, the legal basis for compounding copies narrowed, and microdosing became one way to stretch limited or costly supply.

Is a GLP-1 microdose safer than a standard dose?+

That is not established. No trial has compared a microdosing regimen with standard dosing for safety, so a smaller number on the syringe is not a proven safety margin. As of May 31, 2026, the FDA had received 990 adverse-event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide, some that may be related to overdoses due to dosing errors when people measured a dose themselves, and it warns that compounded products do not undergo its premarket review. Smaller does not automatically mean safer.

What are the labelled starting doses of semaglutide and tirzepatide?+

For the semaglutide injections, the WEGOVY label sets a starting dosage of 0.25 mg subcutaneously once weekly for four weeks before escalating (labelled dose, not a recommendation, WEGOVY FDA label), and the OZEMPIC label sets the same 0.25 mg once-weekly start for four weeks (labelled dose, not a recommendation, OZEMPIC FDA label). For the tirzepatide injections, the ZEPBOUND label sets a starting dosage of 2.5 mg subcutaneously once weekly (labelled dose, not a recommendation, ZEPBOUND FDA label) and states this dose of 2.5 mg (labelled dose, not a recommendation, ZEPBOUND FDA label) is for initiation only and is not approved as a maintenance dosage, while the MOUNJARO label sets the same 2.5 mg once-weekly start (labelled dose, not a recommendation, MOUNJARO FDA label) and increases the dose in increments of 2.5 mg (labelled dose, not a recommendation, MOUNJARO FDA label) if additional glycemic control is needed, naming a maximum rather than a discrete maintenance dose. Each label sets its own titration rather than a single fixed dose.

Sources and references

  1. 1.GLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them? News-Medical.net, September 1, 2026. news-medical.net / GLP-1 microdoses
  2. 2.Considerations and challenges in microdosing of GLP-1-based receptor agonists. Expert Opinion on Pharmacotherapy, 2026. PMID 42788826. PubMed PMID 42788826
  3. 3.I'm a weight-loss doctor. Here's why I worry about GLP-1 'microdoses' (First Opinion by Jody Dushay). STAT News, May 29, 2026. statnews.com / GLP-1 microdose worry
  4. 4.Microdosing aims to extend the lifespan of the GLP-1 compounding market. STAT News, November 4, 2025. statnews.com / microdosing compounding market
  5. 5.The 'microdosing' dilemma: balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions. Journal of the American Association of Nurse Practitioners, 2026. PMID 42201545. PubMed PMID 42201545
  6. 6.Multisystem Benefits of GLP-1 Microdosing: A Narrative Review. Cureus, 2026. PMID 42668762. PubMed PMID 42668762
  7. 7.Microdosing Tirzepatide in Multi-Dose Pens: Clinical Individualization, Safety, and Evidence Gaps. Obesity (Silver Spring), 2026. PMID 42571951. PubMed PMID 42571951
  8. 8.Micro Doses, Macro Potential? Considerations for Microdosing Tirzepatide in Multi-Dose Pens. Obesity (Silver Spring), 2026. PMID 42244165. PubMed PMID 42244165
  9. 9.Comment on Komé et al. One Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose Pens. Diabetes Care, 2025. PMID 40540673. PubMed PMID 40540673
  10. 10.One Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose Pens. Diabetes Care, 2025. PMID 39808463. PubMed PMID 39808463
  11. 11.PubMed search, microdosing AND (GLP-1 OR semaglutide OR tirzepatide), NCBI E-utilities, run September 29, 2026: 11 records returned. PubMed / microdosing GLP-1 search
  12. 12.WEGOVY (semaglutide) injection and tablets, DailyMed label (Novo Nordisk), revised 6/2026. DailyMed / WEGOVY
  13. 13.WEGOVY (semaglutide) Prescribing Information, Novo Nordisk, revised 06/2026. novo-pi.com / WEGOVY PI
  14. 14.OZEMPIC (semaglutide) injection, FDA Prescribing Information, Reference ID 5676363, revised 10/2025. fda.gov / OZEMPIC PI
  15. 15.OZEMPIC (semaglutide) injection, DailyMed label (Novo Nordisk), revised 5/2026. DailyMed / OZEMPIC
  16. 16.ZEPBOUND (tirzepatide) injection, US Prescribing Information, Eli Lilly and Company, revised 08/2026. pi.lilly.com / ZEPBOUND PI
  17. 17.ZEPBOUND (tirzepatide) injection, DailyMed label (Eli Lilly and Company), revised 8/2026. DailyMed / ZEPBOUND
  18. 18.MOUNJARO (tirzepatide) injection, US Prescribing Information, Eli Lilly and Company, revised 08/2026. pi.lilly.com / MOUNJARO PI
  19. 19.MOUNJARO (tirzepatide) injection, DailyMed label (Eli Lilly and Company), revised 8/2026. DailyMed / MOUNJARO
  20. 20.Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet, 2018. PMID 30122305. PubMed PMID 30122305
  21. 21.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022. PMID 35658024. PubMed PMID 35658024
  22. 22.Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 2021. PMID 34170647. PubMed PMID 34170647
  23. 23.FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. US Food and Drug Administration, content current as of 07/26/2024. fda.gov / compounded semaglutide dosing errors
  24. 24.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. US Food and Drug Administration, content current as of 09/01/2026. fda.gov / unapproved GLP-1 drugs
  25. 25.FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. US Food and Drug Administration, content current as of 04/01/2026. fda.gov / compounder policy
  26. 26.Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound). US Food and Drug Administration, December 19, 2024. (Not re-verified: our checker could not retrieve this page.) fda.gov / tirzepatide shortage order
  27. 27.Declaratory Order: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy). US Food and Drug Administration, February 21, 2025. (Not re-verified: our checker could not retrieve this page.) fda.gov / semaglutide shortage order
  28. 28.NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews, 2026. PMID 41655607. PubMed PMID 41655607
  29. 29.EGRIFTA SV (tesamorelin for injection) label. DailyMed, US National Library of Medicine, 2/2024. DailyMed / EGRIFTA SV
  30. 30.MOTS-c: a promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology, 2023. PMID 36761202. PubMed PMID 36761202
  31. 31.VYLEESI (bremelanotide) injection label. DailyMed, US National Library of Medicine, 3/2024. DailyMed / VYLEESI
  32. 32.Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. US Food and Drug Administration, Federal Register document 2013-04827, March 4, 2013 (via govinfo.gov). govinfo.gov / GEREF sermorelin
  33. 33.Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. US Food and Drug Administration, page last updated 04/22/2026. fda.gov / bulk drug substances
  34. 34.SAXENDA (liraglutide) injection label. DailyMed, US National Library of Medicine, 6/2026. DailyMed / SAXENDA
  35. 35.Lithium as a disease-modifying therapy for Parkinson's disease: mechanisms, preclinical evidence, and clinical prospects. Clin Park Relat Disord, 2026. PMID 42170063. PubMed PMID 42170063
  36. 36.Development of a sensitive LC-MS/MS assay to support human microdose study for an oral agonist of the GLP-1 receptor. Bioanalysis, 2024. PMID 39088035. PubMed PMID 39088035
  37. 37.Self-Assembled Oligopeptoplex-Loaded Dissolving Microneedles for Adipocyte-Targeted Anti-Obesity Gene Therapy. Advanced Materials, 2024. PMID 38213134. PubMed PMID 38213134
  38. 38.Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice. Translational Psychiatry, 2022. PMID 35953488. PubMed PMID 35953488

Related reading

Microdosing Tirzepatide

The tirzepatide detail page: labels and practice

Microdosing Semaglutide

The semaglutide detail page: labels and practice

GLP-1 Side Effects

Managing nausea, constipation, and more

Tirzepatide vs Semaglutide

How the two GLP-1 drugs compare

When Will Retatrutide Be Available

Where availability stands

GLP-1 Medicines in Vietnam

How these drugs reach the market here

This guide is for educational purposes only and is not medical advice. It describes what FDA labels and published clinical trials report about the doses they used, and it states plainly where no trial exists. It is not an endorsement, a recommendation, or an instruction to use any compound, and it does not tell anyone what to take. GLP-1 medicines are prescription drugs. Consult a qualified healthcare professional before making any decision about your health.

Sources

Entries marked ° are cited from the publisher, but our checker could not retrieve the page to confirm the wording.

  1. 1.news-medical.net / GLP-1 microdoses
  2. 2.PubMed PMID 42788826
  3. 3.statnews.com / GLP-1 microdose worry
  4. 4.statnews.com / microdosing compounding market
  5. 5.PubMed PMID 42201545
  6. 6.PubMed PMID 42668762
  7. 7.PubMed PMID 42571951
  8. 8.PubMed PMID 42244165
  9. 9.PubMed PMID 40540673
  10. 10.PubMed PMID 39808463
  11. 11.PubMed / microdosing GLP-1 search
  12. 12.DailyMed / WEGOVY
  13. 13.novo-pi.com / WEGOVY PI
  14. 14.fda.gov / OZEMPIC PI
  15. 15.DailyMed / OZEMPIC
  16. 16.pi.lilly.com / ZEPBOUND PI
  17. 17.DailyMed / ZEPBOUND
  18. 18.pi.lilly.com / MOUNJARO PI
  19. 19.DailyMed / MOUNJARO
  20. 20.PubMed PMID 30122305
  21. 21.PubMed PMID 35658024
  22. 22.PubMed PMID 34170647
  23. 23.fda.gov / compounded semaglutide dosing errors
  24. 24.fda.gov / unapproved GLP-1 drugs
  25. 25.fda.gov / compounder policy
  26. 26.fda.gov / tirzepatide shortage order°
  27. 27.fda.gov / semaglutide shortage order°
  28. 28.PubMed PMID 41655607
  29. 29.DailyMed / EGRIFTA SV
  30. 30.PubMed PMID 36761202
  31. 31.DailyMed / VYLEESI
  32. 32.govinfo.gov / GEREF sermorelin
  33. 33.fda.gov / bulk drug substances
  34. 34.DailyMed / SAXENDA
  35. 35.PubMed PMID 42170063
  36. 36.PubMed PMID 39088035
  37. 37.PubMed PMID 38213134
  38. 38.PubMed PMID 35953488